EN DE
Watch S.Biomedics Co. Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

S.Biomedics Co. Ltd. (304360) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of S.Biomedics Co. Ltd. stock KRW 12,453, price KRW 18,160, that is 31.4% below the price, quality 29 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

SB S.Biomedics Co. Ltd. logo Thin data Nov 10, 2026

S.Biomedics Co. Ltd.

304360 · KQ
Expensive, weak quality

Our calculation puts a fair price 31% below what the stock costs today.

Expensive Growth (revenue 3y +11.0 %/yr in KRW)
Moderate debt
Fair value 12,453 KRW · Overvalued
Quality 29/100
Loss-making · -73.1% net margin (TTM)
Negative free cash flow
Trails peers (2/10)
Narrow moat 12/100
Thin data
Estimate
Watch S.Biomedics Co. Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

48,850 KRW 6,960 KRW Fair Value 12,453 KRW May 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

42‑month range 6,960 KRW – 48,850 KRW · fair‑value band 9,340 KRW – 15,566 KRW · the 18,160 KRW price screens above the 12,453 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow S.Biomedics Co. in your weekly email

Every Wednesday you see whether S.Biomedics Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products.

Show moreShow less

Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson's disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration; CF-TED-N for the treatment of stroke; and CF-FECS-DF for the treatment of wound.

The company provides testing services; and owns platform technologies for developing cell therapy products.

The company has a strategic partnership with Catalent, Inc. for the development and manufacturing of TED-A9. S.Biomedics CO., LTD. was founded in 2005 and is headquartered in Seoul, South Korea.

Stock analysis

S.Biomedics Co. Ltd. (304360) currently trades at 18,160 KRW, while our estimate is 12,453 KRW, 31% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 9,340 KRW (bear) to 15,566 KRW (bull), the price of 18,160 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

S.Biomedics Co. Ltd. reported revenue of 16.5B KRW in FY2025 versus 8.9B KRW in FY2021, a compound +16.9%/yr. Reported net income was −8.1B KRW in FY2025.

Key figures

Market cap 238B KRW (≈ $178M) Micro · P/S ratio 14.4 · EPS (TTM) −973.61 KRW · Net margin −73.1% · Return on equity −39.3% · Return on assets (EBIT) −18.4% (5-year average) · Operating margin −76.5% · Revenue (TTM) 16.5B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 55% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −31%, 304360 screens richer than that median.

Fair Value

Bear 9,340 KRW Fair Value 12,453 KRW Bull 15,566 KRW
Price 18,160 KRW · Downside -31.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 11
How much profit the company makes from its sales and capital
Quality Growth 57
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 51
Debt, balance sheet and risk of trouble
Investment 2
Does it invest with discipline instead of growing at any price?
Low Volatility 13
How calm the share price moves, does not count
Price momentum 22
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 10
Distance to the 52-week high, does not count
New shares 59
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 31/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+20.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−52.2% (2021) → −50.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

304360 screens overvalued: fair value 31% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare S.Biomedics Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −31.4% · Below median
Profitability
Return on assets −19.7% · Above median
Net margin (12 months) −73.1% · Bottom 25%
Operating margin (12 months) −76.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.2% · Above median
Balance sheet
Debt / equity 0.70× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 27.39× · Priciest 25%
P/S (12 months) 14.41× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)1 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)65 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 304360
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 304360
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 304360
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 304360
argenx SE ARGX $971.55 $908.40 −7% vs 304360
CSL Limited CSL A$201.68 A$181.40 −10% vs 304360
Moderna, Inc MRNA $250.83 $158.70 −37% vs 304360
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 304360
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 304360
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 304360

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

S.Biomedics Co. Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "S.Biomedics Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/304360

Frequently asked questions

Is S.Biomedics Co. Ltd. (304360) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 12,453 KRW versus a price of 18,160 KRW, about 31% lower (overvalued).
What is the fair value of 304360?
Our estimate for S.Biomedics Co. Ltd. is 12,453 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 18,160 KRW.
What is the quality score of 304360?
S.Biomedics Co. Ltd. has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for S.Biomedics Co. Ltd. (304360)?
Our calculated price target is the estimate of 12,453 KRW (as of Nov 10, 2026). Cautious scenario 9,340 KRW, optimistic scenario 15,566 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the S.Biomedics Co. Ltd. stock forecast for 2026?
Our estimate puts fair value at 12,453 KRW, about 31% lower versus a price of 18,160 KRW (overvalued). Cautious scenario 9,340 KRW, optimistic scenario 15,566 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of S.Biomedics Co. Ltd. (304360)?
S.Biomedics Co. Ltd. reported trailing-twelve-month revenue of about 16.5B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of S.Biomedics Co. Ltd. (304360)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For S.Biomedics Co. Ltd. it is 12,453 KRW per share (as of Nov 10, 2026), against a price of 18,160 KRW.
Is S.Biomedics Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 304360 trades above its calculated fair value: price 18,160 KRW, fair value 12,453 KRW, a gap of about −31% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 304360?
No. The price is what the market pays today (18,160 KRW); the fair value is what the company's own numbers justify (12,453 KRW). For S.Biomedics Co. Ltd. the two are 5,707 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is S.Biomedics Co. Ltd. worth?
The market values S.Biomedics Co. Ltd. at about 238B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 18,160 KRW; our models calculate a fair value of 12,453 KRW per share.
What do the bullish and bearish scenarios say about 304360?
Our models span a range for S.Biomedics Co. Ltd.: cautious scenario 9,340 KRW, base 12,453 KRW, optimistic 15,566 KRW per share (as of Nov 10, 2026, price 18,160 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of S.Biomedics Co. Ltd. (304360)?
Balance-sheet figures for S.Biomedics Co. Ltd. (as of Nov 10, 2026): return on equity −39.3%, debt of 0.70 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is 304360 from its 52-week high?
S.Biomedics Co. Ltd. trades at 18,160 KRW, about 55% below its 52-week high of 40,450 KRW and 20% above the low of 15,100 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 12,453 KRW is for.
Which stocks are comparable to S.Biomedics Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is S.Biomedics Co. Ltd. stock attractive at the current price?
The data as of Nov 10, 2026: price 18,160 KRW, calculated fair value 12,453 KRW (−31%), Quality Score 29/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. S.Biomedics Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of S.Biomedics Co. Ltd. (304360)?
The closing price on Nov 10, 2026 was 18,160 KRW. Our estimate is 12,453 KRW, about 31% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with S.Biomedics Co. Ltd. right now?
The price sits above even our optimistic bull case (15,566 KRW). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of S.Biomedics Co. Ltd.

How large is the market capitalisation of S.Biomedics Co. Ltd. (304360)?
The market capitalisation of S.Biomedics Co. Ltd. is 238B KRW (≈ $178M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of S.Biomedics Co. Ltd. (304360)?
The price-to-sales ratio of S.Biomedics Co. Ltd. is 14.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of S.Biomedics Co. Ltd. (304360)?
Earnings per share at S.Biomedics Co. Ltd. are −973.61 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of S.Biomedics Co. Ltd. (304360)?
The net margin of S.Biomedics Co. Ltd. is −73.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of S.Biomedics Co. Ltd. (304360)?
The return on equity (ROE) of S.Biomedics Co. Ltd. is −39.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of S.Biomedics Co. Ltd. (304360)?
On an EBIT basis the return on assets of S.Biomedics Co. Ltd. is −18.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of S.Biomedics Co. Ltd. (304360)?
The operating margin of S.Biomedics Co. Ltd. is −76.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at S.Biomedics Co. Ltd. (304360)?
Revenue at S.Biomedics Co. Ltd. is growing +0.2% versus a year earlier (3y avg +11.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does S.Biomedics Co. Ltd. (304360) generate?
The free cash flow of S.Biomedics Co. Ltd. is −8.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does S.Biomedics Co. Ltd. (304360) carry?
The net debt of S.Biomedics Co. Ltd. is 4.6B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch S.Biomedics Co. Ltd. in the live analysis

One click puts S.Biomedics Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.